Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BRENTUXIMAB VEDOTIN Cause Bone marrow failure? 48 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 48 reports of Bone marrow failure have been filed in association with BRENTUXIMAB VEDOTIN (ADCETRIS). This represents 0.5% of all adverse event reports for BRENTUXIMAB VEDOTIN.

48
Reports of Bone marrow failure with BRENTUXIMAB VEDOTIN
0.5%
of all BRENTUXIMAB VEDOTIN reports
17
Deaths
15
Hospitalizations

How Dangerous Is Bone marrow failure From BRENTUXIMAB VEDOTIN?

Of the 48 reports, 17 (35.4%) resulted in death, 15 (31.3%) required hospitalization, and 5 (10.4%) were considered life-threatening.

Is Bone marrow failure Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BRENTUXIMAB VEDOTIN. However, 48 reports have been filed with the FAERS database.

What Other Side Effects Does BRENTUXIMAB VEDOTIN Cause?

Off label use (1,370) Neuropathy peripheral (695) Pyrexia (693) Febrile neutropenia (684) Death (602) Neutropenia (561) Hodgkin's disease (512) Nausea (392) Diarrhoea (385) Anaemia (374)

What Other Drugs Cause Bone marrow failure?

CYCLOPHOSPHAMIDE (1,834) METHOTREXATE (1,401) ETOPOSIDE (1,081) RITUXIMAB (1,060) CYTARABINE (1,052) VINCRISTINE (1,001) DOXORUBICIN (1,000) PALBOCICLIB (951) CARBOPLATIN (855) BEVACIZUMAB (835)

Which BRENTUXIMAB VEDOTIN Alternatives Have Lower Bone marrow failure Risk?

BRENTUXIMAB VEDOTIN vs BREO ELLIPTA BRENTUXIMAB VEDOTIN vs BREXANOLONE BRENTUXIMAB VEDOTIN vs BREXPIPRAZOLE BRENTUXIMAB VEDOTIN vs BREXUCABTAGENE AUTOLEUCEL BRENTUXIMAB VEDOTIN vs BRIGATINIB

Related Pages

BRENTUXIMAB VEDOTIN Full Profile All Bone marrow failure Reports All Drugs Causing Bone marrow failure BRENTUXIMAB VEDOTIN Demographics